Truist Securities Reiterates Buy on Madrigal Pharmaceuticals, Raises Price Target to $743

Benzinga · 1d ago
Truist Securities analyst Srikripa Devarakonda reiterates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $709 to $743.